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HYPERTENSION IN OCTOGENERIANS
Hypotension is more risky than hypertension in very
old people
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The open label treatment extension of the original HYVET
study received enthusiastic applause as further evidence for
direct and long term benefits of treating hypertension in very
old people (≥80 years).1 However, we should be cautious in
extrapolating these findings to clinical practice.
It has repeatedly been shown that hypotension, not hypertension,
carries the greatest risk in very old people.2 Low blood pressure
may be a consequence of imminent heart failure, drug treatment,
or both, whereas raised blood pressure may be reactive and can
have survival benefits by ensuring perfusion in critical organs.3
It is therefore important to estimate the net benefit of blood
pressure lowering treatment. The latest Cochrane review on
treatment of hypertension in octogenarians weighs all the
available evidence, including the HYVET study, but does not
show a survival benefit for treatment, the hazard ratio being
close to unity.4 The HYVET studymay be the only trial to show
a survival benefit because it recruited healthy octogenarians, as
shown by the low levels of comorbidity at baseline and low
fatality rate in the placebo group.5
The benefits of treating very healthy octogenarians with
hypertension definitely outweigh the side effects. But it would
be a daunting task for clinicians to correctly identify these older
people in clinical practice.
Competing interests: None declared.
1 Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, et al; for the HYVET Study
Group. Immediate and late benefits of treating very elderly people with hypertension:
results from active treatment extension to Hypertension in the Very Elderly randomised
controlled trial. BMJ 2012;344:d7541. (4 January.)
2 Van Bemmel T, Gussekloo J, Westendorp RG, Blauw GJ. In a population-based
prospective study, no association between high blood pressure and mortality after age
85 years. J Hypertens 2006;24:287-92.
3 Euser SM, van Bemmel T, Schram MT, Gussekloo J, Hofman A, Westendorp RG, et al.
The effect of age on the association between blood pressure and cognitive function later
in life. J Am Geriatr Soc 2009;57:1232-7.
4 Musini VM, Tejani AM, Basset K, Wright JM. Pharmacotherapy for hypertension in the
elderly. Cochrane Database Syst Rev 2009;4:CD000028.
5 Beckett N, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of
hypertension in patients 80 years of age or older. N Engl J Med 2008;358:18.
Cite this as: BMJ 2012;344:e721
© BMJ Publishing Group Ltd 2012
engelaer@leydenacademy.nl
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e721 doi: 10.1136/bmj.e721 (Published 31 January 2012) Page 1 of 1
Letters
LETTERS
